Costs of hospital events in patients with metastatic colorectal cancer

Journal of Medical Economics

Volumn 14, Issue 5, 2011, Pages 656-661

  Overbeek, Jetty A ^a   Zhao, Zhongyun ^b   Van Herk Sukel, Myrthe P P ^a   Barber, Beth L ^b   Gao, Sue ^b   Herings, Ron M C ^a,c  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b AMGEN INC   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Costs; Hospital event; Metastatic colorectal cancer; Oncology

Indexed keywords

BEVACIZUMAB; CETUXIMAB; PANITUMUMAB;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; DISTANT METASTASIS; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITALIZATION; HUMAN; HYPERTENSION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUTROPENIA; OUTCOME ASSESSMENT; SEPSIS; SKIN DISEASE; STROKE; VENOUS THROMBOEMBOLISM; WOUND HEALING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NETHERLANDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052745068     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.610394     Document Type: Article

References (13)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
2. Ramsey SD, Berry K, Etzioni R. Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer. Am J Gastroenterol 2002; 97:440-5
3. van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, et al. New opportunities for drug outcomes research in cancer patients: The linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer 2010;46:395-404
4. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 2010;28:4697-705
5. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706-13
6. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptortargeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101:1308-24
7. van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408-17
8. Scheer MG, Sloots CE, van der Wilt GJ, et al. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol 2008;19:1829-35
9. Fu AZ, Zhao Z, Wang S, et al. Hospital costs of adverse events in patients receiving treatment for metastatic colorectal cancer. Value Health 2011;14:A173
10. Dutch Hospital Data. Available online at: Http://www.dutchhospitaldata. nl. Accessed 18 August 2011
11. Song X, Zhao Z, Barber B, et al. Cost of illness in patients with metastatic colorectal cancer. J Med Econ 2011;14:1-9
12. Song X, Zhao Z, Barber B, et al. Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics. Curr Med Res Opin 2011;27:123-30
13. The Dutch Healthcare Authority. Available online at: Http://www.nza.nl. Accessed 18 August 2011